Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Telik, a clinical stage drug development company, has announced that it is implementing a reorganization to focus on its preclinical and clinical drug development programs. The restructuring will involve a workforce reduction of 44% primarily in early-stage discovery and support positions.
Subscribe to our email newsletter
According to the company, employees directly affected by the restructuring plan will receive severance payments, continuation of benefits and outplacement assistance. The company estimates incurring personnel-related restructuring charges of approximately $0.9 million in the first quarter of 2009.
The reorganization will enable the company to continue the development of Telintra and two preclinical drug candidates: a prodrug cytotoxic, TLK58747, and dual Aurora-VEGFR kinase inhibitor, TLK60404.
Michael Wick, chairman and CEO of Telik, said: “This reorganization will allow us to focus our resources on the clinical development of our lead compound, Telintra, currently in Phase II studies for myleodysplastic syndrome and chemotherapy induced neutropenia, as well as other potential indications. We also plan to advance our two leading preclinical drug candidates and continue to support our Trap technology collaborations.”